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Objectives: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia world-
wide, affecting about 5% of the population over 60 years old. This condition is asso-
ciated with an increased risk of arterial thromboembolism and stroke particularly 
ischemic stroke. Anticoagulant therapy can substantially reduce these complica-
tions. The aim of this analysis is to estimate the non pharmacological costs and 
consequences of the use of apixaban compared with warfarin in the treatment of 
patients with non-valvular atrial fibrillation (NVAF) in Colombia. MethOds: An 
excel model was adapted to simulate the cost and outcomes based on a hypothetic 
cohort of 1,000,000 patients annually. The comparators were: apixaban (5 mg BID) 
with warfarin (INR 2.0 to 3.0). The prevalence of AF data was taken from a local study 
.The effectiveness and safety data were taken from ARISTOTLE study (n= 18,201). 
The analysis used the third payer perspective including only direct medical costs. 
The costs of medical procedures were taken from the ISS tariffs and expressed in 
2013 $ US (1 $ US= 1.934 COP). The results were measured in terms of number of 
events of stroke/systemic embolism, major bleedings and deaths presented annu-
ally. Results: The results were as follows: events of stroke/systemic embolism 
apixaban 73 and warfarina 93; major bleedings apixaban 123 and warfarina 179; 
and deaths apixaban 203 and warfarina 228. The Model results indicate that apixa-
ban compared to enoxaparin would prevent per year: 20 stroke/systemic embolism 
events, 56 major bleedings and 25 deaths. Apixaban compared with warfarin would 
save annually on average $ US 184,227 for the cohort of simulated patients, distrib-
uted as follows: $ US 85,938 (47 %) in care of stroke/systemic embolism and $ US 
98,262 (53 %) in care of major bleedings. cOnclusiOns: In this analysis, apixaban 
demonstrates better expected health outcomes with lower expected associated 
costs, in the Colombian health system.
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Objectives: Thrombolysis has not been fully implemented into clinical practice in 
the developing world primarily due to economic restraints. The study assessed the 
cost-effectiveness (CE) and estimated annual savings of thrombolysis with recom-
binant tissue plasminogen activator (rt-PA, alteplase) within 4.5 hours after acute 
ischemic stroke (AIS) versus standard care from the Mexican Institute of Social 
Security (IMSS) perspective. Standard care (SC) was defined as inpatient treatment of 
the AIS without utilization of thrombolytic agents. MethOds: A decision-analytic 
model was developed. Efficacy, direct costs and resources were obtained from IMSS 
available data and published studies. Effectiveness outcomes included the percent-
age of patients who responded favorably to treatment (no disability and able to 
carry out all usual activities) between the time of diagnosis + 1 year (time horizon). 
Additionally analyses evaluated cost savings in patients with AIS (> 80 years old) 
who responded favorably to the treatment. Discount rates were not applied to the 
model. A sensitivity analysis was conducted to evaluate the impact of the uncer-
tainty variables. Results: The estimated total cost per patient was $23,53.20 for 
SC and $23,663.93 for rt-PA. The percentage of patients who responded favorably 
to treatment was 16% in the rt-PA and 12% in SC. The CER were USD $193,241.02 
for SC and USD$146,924.34 for rt-PA. This equated to a cost-savings of $46,316.67/
percentage of patients recovered with no symptoms/disabilities. The projected sav-
ings over a five-year period (2013-2017) in the IMSS ranged from $9,626,458 and 
$22,015,454. cOnclusiOns: The results from the analyses indicated that rt-PA pro-
vided a highly cost-effective and saving alternative compared with SC. In medical 
settings where thrombolysis is not yet a common practice, rt-PA is a cost effective 
treatment to improve functional outcome in patients treated promptly after acute 
ischemic stroke.
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Objectives: To analyse the incremental cost-effectiveness ratio (ICER) between 
combination angiotensin II receptor antagonists + thiazides. Specifically, compar-
ing azilsartan + clortalidona vs. current available treatments: valsartan + hydro-
chlorothiazide, telmisartan + hydrochlorothiazide, losartan + hydrochlorothiazide 
and irbesartan + hydrochlorothiazide. MethOds: Cost-effectiveness analysis was 
conducted using a Markov model with a 35-year temporal horizon for patients 
over the age of 45 and diagnosed with systemic arterial hypertension. The model 
adopts the Mexican public health institutions’ perspective. Four health states were 
incorporated: healthy, hypertensive with non-fatal acute myocardial infarction 
(AMI), hypertensive with non-fatal stroke and death. Transition probabilities were 
calculated based on the national risk of stroke or AMI, and the probability of hav-
ing a vascular complication depending on blood pressure levels (in mmHg). Costs 
and effectiveness data were taken from public health institutions, producer phar-
maceutical companies or extracted from published literature. Final outcome was 
measured in ICER per life year gained (LYG). Cost-effectiveness was determined 
according to the 1GDP/capita threshold established by the National Health Council 
in Mexico. Results: Azilsartan + chlortalidone was found to be dominant com-
pared to all other treatments with a total cost of USD$2,873.57 over 35 years, and 
an effectiveness of 12.23 LYG. The next most cost-effective comparator, losartan + 
hydrochlorothiazide, presented an ICER of USD$349.21; however due to a difference 
in efficacy of -0.68 LYG, azilsartan + chlortalidone remained dominant even with a 
10% increase in price. cOnclusiOns: Azilsartan + chlortalidone was found to be 
dominant in comparison with all other included treatments. Azilsartan is therefore 
a very cost-effective intervention for the Mexican population over 45 with systemic 
arterial hypertension.
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Objectives: To compare costs and effectiveness of dabigatran versus factor 
Xa inhibitors (apixaban and rivaroxaban) in patients with non-valvular atrial 
fibrillation (NVAF) from a private and public health care system perspective in 
Brazil. MethOds: The cost-effectiveness analysis was based on Markov modeling, 
and estimated the costs and clinical outcomes, in a lifetime horizon, associated to 
dabigatran, apixaban and rivaroxaban in patients with NVAF. Epidemiological and 
efficacy data derived from international literature and a modified Delphi panel 
with Brazilian experts (local clinical practice pattern on the management of NVAF 
patients). The model estimated the number of events (ischaemic strokes, systemic 
embolisms, transient ischaemic attacks) associated with the respective treatments. 
To each clinical event costs, disabilities and/or reduction in quality of life, and risk 
of death were assigned. Only direct medical costs were considered and obtained 
from Brazilian official databases. Costs and benefits were discounted at 5% yearly, 
according to Brazilian Health Technologies Assessment guidelines. Sensitivity analy-
sis was designed to assess uncertainty. Results: Considering 100 patients, base 
case analysis showed that dabigatran was associated with additional 4.6 life years 
(LY), additional 4.3 QALYs, and demonstrated a lower incidence of events (1,4 events 
avoided) versus apixaban. Compared to rivaroxaban, dabigatran was also associ-
ated with additional 17.8 life years (LY), additional 19.3 QALYs, and demonstrated a 
lower incidence of events (2.8 events avoided). Under both perspectives and versus 
both comparators, dabigatran was associated with lower costs. Sensitivity analyses 
confirmed the favorable results of the base case. cOnclusiOns: Findings suggest 
that dabigatran is a dominant option for stroke prevention when used instead of 
direct factor Xa inhibitors (apixaban or rivaroxaban) in NVAF patients from the 
Brazilian public and private health care system perspective.
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Objectives: The purpose of this study was to assess the predictive validity of an 
apixaban cost-effectiveness model by comparing key event rates from the model 
to those seen in the ARISTOTLE trial where apixaban was compared with vitamin K 
antagonist (VKA) in patients with non-valvular atrial fibrillation (NVAF). MethOds: 
A Markov model was developed to assess the cost effectiveness of apixaban versus 
comparators including VKA. The model was set to the settings of the ARISTOTLE 
and the key event rates were compared by setting time horizon same as ARISTOTLE. 
Predictive validity of the model was checked by comparing key outcomes to the 
source data. Results: Overall, the model closely predicted event-based hazard ratio 
(HR) for warfarin versus apixaban for various end-points including ischemic and 
unspecified stroke (HR: 1.09 vs 1.08 for trial vs. model). Similar results were observed 
for intracranial hemorrhages (HR: 2.38 vs. 2.25), other major bleeds (HR: 1.27 vs. 1.24) 
and myocardial infarction (HR: 1.14 vs. 1.13). Importantly, death was accurately pre-
dicted by this model with HR of 1.13 vs. 1.12 seen in the trial. Slight variations in the 
HR may be attributable to the sequential structure of the model where event rates 
associated with aspirin therapy after warfarin discontinuation were derived from 
AVERROES patients on aspirin who were previously treated with warfarin (@42%). 
Other major bleeds and clinically relevant non-major bleeds rates were slightly 
different, as these events were modeled as transient states to mimic real life treat-
ment patterns. cOnclusiOns: The model appears to predict event rates seen in 
ARISTOTLE trial, thus demonstrating the model’s ability to accurately replicate the 
trial results within the trial period. This study demonstrates the applicability of this 
model to estimate cost-effectiveness of new interventions in similar populations.
PCV68
CosT effeCTiVeNess of drug eluTiNg ballooN Versus PerCuTaNeous 
TraNslumiNal ballooN aNgioPlasTy, bare meTal sTeNT aNd drug 
eluTiNg sTeNT iN The TreaTmeNT of PeriPheral arTerial disease iN 
loWer limbs Colombia
Orozco J.J., Valencia J.E., Sardi C.
Medtronic Latinamerica Inc., Bogota, Colombia
Objectives: Cost-Effectiveness analysis of Drug Eluting Balloon (DEB) vs. 
Percutaneous Transluminal Balloon Angioplasty (PTA), Bare Metal Stent (BMS) and 
